Malignancies after Mitoxantrone for Multiple Sclerosis
Neurol 86:2203-2207, Buttmann, M.,et al, 2016
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Acute Myeloid Leukemia in Italian Patients with Multiple Sclerosis Treated with Mitoxantrone
Neurol 77:1887-1895, Martinelli, V.,et al, 2011
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Cardiotoxicity and Other Adverse Events Associated With Mitoxantrone Treatment for MS
Neurol 74:1822-1826, Kingwell,E., et al, 2010
Severe Cardiac Failure in a Patient with Multiple Sclerosis Following Low-Dose Mitoxantrone Treatment
Neurol 73:991-993, D�rr,J.,et al, 2009
Mitoxantrone for Multiple Sclerosis Causing Acute Lymphoblastic Leukemia
Neurol 68:1630-1631, Cartwright,M.S.,et al, 2007
The Use of Mitoxantrone (Novantrone) for the Treatment of Multiple Sclerosis
Neurol 61:1332-1338, Goodin,D.S.,et al, 2003
Mitoxantrone in Progressive Multiple Sclerosis: A Placebo-Controlled, Double-Blind, Randomised, Multicentre Trial
Lancet 360:2018-2025, Hartung,H.,et al, 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001